Cabozantinib/ nivolumab/ipilimumab improves progression-free survival versus dual nivolumab/ipilimumab in untreated advanced renal cell carcinoma.
Both antibiotic use and days with antibiotic use could be markedly reduced with the help of a procalcitonin-based algorithm.
Phase 3 Checkmate 914 trial showed that the adjuvant treatment does not improve survival for stage II–III localised RCC, which has high post-nephrectomy risk.
In Antarctica, thirteen people are cut off from the world for nine months. Among them, a physician with heavy duties, yet in an extraordinary adventure.
Early surgery might benefit Crohn's patients, but identifying exact patient groups who will benefit from early surgery requires prospective studies.
Compared to conventional colonoscopy, the addition of artificial intelligence entailed significantly higher detection and lower rates of missed adenomas.
Second-line treatment with TIL improves PFS compared with ipilimumab in patients with advanced, non-resectable stage III–IV melanoma.
Symptom control maintenance after 40 weeks was investigated in mirikizumab responders after a 12 week induction therapy.
Brepocitinib demonstrated significant efficacy in Hidradenitis Suppurativa Clinical Response (HiSCR) and flare reduction in hidradenitis suppurativa (HS).
Which technologies are useful for nursing home residents? And how can they be designed to respect their needs and protect their dignity?
Significantly less ulcer bleeding was found in patients with chronic aspirin use who underwent eradication of Helicobacter pylori, according to HEAT trial results.
Up to 80.6% of Phase 3 ADvocate trial responders, based on dosing interval, stayed clear or almost clear of lesions from weeks 16 to 52, according to the IGA scale.
In the phase 3 EoE KIDS trial, dupilumab showed remarkable efficacy in paediatric patients with eosinophilic oesophagitis.
A second phase 2 trial showed prurigo nodularis patients treated with dupilumab had a remarkable itch improvement from baseline to week 24.
For the first time, a study assessed longitudinal changes in microbiota during therapy with immune checkpoint inhibitors (ICIs).
Follow-up >6 months for necrotising pancreatitis infections with immediate or delayed drainage showed no influence on mortality or major complications.
Drugs for mental health? That may still seem strange to some. We explain what physicians need to know about novel forms of therapy with psychedelic substances.
Crohn's patients who responded only after a risankizumab second induction kept a CDAI clinical response in 75.8% on subcutaneous 360 mg at week 52.
Dr Adak Pirmorady-Sehouli talks in an interview about creative writing as a form of therapy in gynaecological oncology and how it can help in treatment.
Upadacitinib led to remission rates and endoscopic response in almost half of intensively pretreated patients with moderate-to-severe Crohn's at week 12.